262 related articles for article (PubMed ID: 20006922)
41. Renal involvement in preeclampsia: similarities to VEGF ablation therapy.
Müller-Deile J; Schiffer M
J Pregnancy; 2011; 2011():176973. PubMed ID: 21494322
[TBL] [Abstract][Full Text] [Related]
42. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM; Langenberg MH; Witteveen E; Voest EE
Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
[TBL] [Abstract][Full Text] [Related]
43. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
44. VEGF inhibition, hypertension, and renal toxicity.
Hayman SR; Leung N; Grande JP; Garovic VD
Curr Oncol Rep; 2012 Aug; 14(4):285-94. PubMed ID: 22544560
[TBL] [Abstract][Full Text] [Related]
45. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Bollée G; Patey N; Cazajous G; Robert C; Goujon JM; Fakhouri F; Bruneval P; Noël LH; Knebelmann B
Nephrol Dial Transplant; 2009 Feb; 24(2):682-5. PubMed ID: 19054798
[TBL] [Abstract][Full Text] [Related]
46. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
47. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
48. Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.
Hayman SR; Calle JC; Jatoi A; Craici IM; Wagner SJ; Weaver AL; Greene EL; Grande JP; Garovic VD
Oncology; 2014; 86(5-6):271-8. PubMed ID: 24902997
[TBL] [Abstract][Full Text] [Related]
49. Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.
Robinson CH; Hart-Matyas M; Morgenstern DA; Noone D; Campisi P
Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):119-123. PubMed ID: 37439024
[TBL] [Abstract][Full Text] [Related]
50. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity].
Clou E; Luque Y
Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486
[TBL] [Abstract][Full Text] [Related]
51. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC
Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of the VEGF signalling pathway and glomerular disorders.
Ollero M; Sahali D
Nephrol Dial Transplant; 2015 Sep; 30(9):1449-55. PubMed ID: 25480873
[TBL] [Abstract][Full Text] [Related]
53. Proteinuria and hypertension with tyrosine kinase inhibitors.
Kandula P; Agarwal R
Kidney Int; 2011 Dec; 80(12):1271-7. PubMed ID: 21900879
[TBL] [Abstract][Full Text] [Related]
54. Renal thrombotic microangiopathy caused by bevacizumab.
Horino T; Ichii O; Shimamura Y; Terada Y
Nephrology (Carlton); 2018 Apr; 23(4):378-379. PubMed ID: 29520904
[No Abstract] [Full Text] [Related]
55. Etiology of angiogenesis inhibition-related hypertension.
Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
J Clin Pathol; 2024 Jun; 77(7):471-477. PubMed ID: 38242556
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Touzani F; Geers C; Pozdzik A
Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470
[TBL] [Abstract][Full Text] [Related]
58. Glomerular disease related to anti-VEGF therapy.
Stokes MB; Erazo MC; D'Agati VD
Kidney Int; 2008 Dec; 74(11):1487-91. PubMed ID: 18547991
[No Abstract] [Full Text] [Related]
59. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
Pandey AK; Singhi EK; Arroyo JP; Ikizler TA; Gould ER; Brown J; Beckman JA; Harrison DG; Moslehi J
Hypertension; 2018 Feb; 71(2):e1-e8. PubMed ID: 29279311
[No Abstract] [Full Text] [Related]
60. How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor.
Rashidi A; Wanchoo R; Izzedine H
Clin J Am Soc Nephrol; 2023 Jan; 18(1):121-123. PubMed ID: 35977777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
